Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Thomas Jefferson University
Headquarters: Philadelphia, PA, United States of America
Website: http://www.jefferson.edu
Year Founded: 1824
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Jul 8, 2022
Management Tracks
BI’s Fine becomes president of R&D at EvolveImmune
Plus Sallah joins Genespire as CMO, and updates from Kinaset, Andera, Ariceum and more
BioCentury | Apr 22, 2021
Emerging Company Profile
Code Bio: Using DNA scaffolds to deliver non-viral gene therapies
Emerging Company Profile: Code Bio aims to deliver larger genetic material than viral vectors can hold
BioCentury | Dec 2, 2020
Distillery Therapeutics
Oligodendrocyte-derived extracellular vesicles for multiple sclerosis
DISEASE CATEGORY: Autoimmune disease
INDICATION: Multiple sclerosis (MS) Extracellular vesicles derived from oligodendrocytes could prevent and treat MS. The vesicles were collected from the
INDICATION: Multiple sclerosis (MS) Extracellular vesicles derived from oligodendrocytes could prevent and treat MS. The vesicles were collected from the
BioCentury | Jul 18, 2020
Finance
Spark vet Furey steering Imvax into glioblastoma Phase II with $112M series C
BioCentury | Apr 10, 2020
Product Development
COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Aug 8, 2019
Emerging Company Profile
Akrevia: Masking immunotherapies en route to tumors
Akrevia is getting around immunotherapy toxicity by masking biologics until they reach tumor microenvironment
BioCentury | May 24, 2019
Emerging Company Profile
Anima opens new target space in translational control
How Anima is leveraging its translational control platform to pursue new targets, small molecules and big pharma deals
Items per page:
1 - 10 of 108